Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$7.77 - $12.47 $1.81 Million - $2.91 Million
-233,114 Reduced 77.46%
67,842 $592,000
Q4 2022

Feb 14, 2023

SELL
$5.52 - $8.48 $140,732 - $216,197
-25,495 Reduced 7.81%
300,956 $0
Q3 2022

Nov 14, 2022

SELL
$4.75 - $8.01 $32,300 - $54,468
-6,800 Reduced 2.04%
326,451 $1.59 Billion
Q2 2022

Aug 12, 2022

BUY
$2.21 - $5.56 $541,408 - $1.36 Million
244,981 Added 277.54%
333,251 $1.85 Million
Q1 2022

May 16, 2022

BUY
$5.07 - $13.68 $447,528 - $1.21 Million
88,270 New
88,270 $447,000

Others Institutions Holding RAIN

About Rain Therapeutics Inc.


  • Ticker RAIN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,837,400
  • Description
  • Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...
More about RAIN
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.